1. Home
  2. INSG vs IPHA Comparison

INSG vs IPHA Comparison

Compare INSG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inseego Corp.

INSG

Inseego Corp.

HOLD

Current Price

$12.17

Market Cap

190.1M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$2.05

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INSG
IPHA
Founded
1996
1999
Country
United States
France
Employees
N/A
163
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.1M
189.5M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
INSG
IPHA
Price
$12.17
$2.05
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$15.33
$5.75
AVG Volume (30 Days)
284.4K
127.5K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.65
N/A
Revenue
$313,832,000.00
N/A
Revenue This Year
$16.21
$180.36
Revenue Next Year
$13.28
N/A
P/E Ratio
$18.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.28
$1.18
52 Week High
$21.90
$2.63

Technical Indicators

Market Signals
Indicator
INSG
IPHA
Relative Strength Index (RSI) 36.04 59.12
Support Level $9.95 $1.72
Resistance Level $13.08 $2.34
Average True Range (ATR) 1.27 0.21
MACD -0.70 0.07
Stochastic Oscillator 2.38 53.08

Price Performance

Historical Comparison
INSG
IPHA

About INSG Inseego Corp.

Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: